FDA approves Genentech's Vabysmo to treat two causes of vision loss | Seeking Alpha

Retrieved on: 2022-01-31 05:18:33

Tags for this article:

Click the tags to see associated articles and topics

FDA approves Genentech's Vabysmo to treat two causes of vision loss | Seeking Alpha. View article details on hiswai:

Excerpt

Genentech, a member of the Roche Group (RHHBY) announces that the FDA has approved Vabysmo (faricimab-svoa) for the treatment of wet, ...

Article found on: seekingalpha.com